On October 1, 2025, Unified filed an amicus brief in MSN Pharmaceuticals, Inc. v. Novartis Pharmaceuticals Corporation (Case No. 25-225). This brief relates to when after-arising technology may be used to assess compliance with 35 U.S.C. § 112.
Unified Patents is represented by Chad Landmon and Kendall Gurule with Polsinelli, and by in-house counsel, Jonathan Stroud. Download the amicus brief below.